Moderate to severe acute pain disturbs motor cortex intracortical inhibition and facilitation in orthopedic trauma patients : a TMS study by Jodoin, Marianne et al.
PLOS ONE
 
Moderate to severe acute pain disturbs motor cortex intracortical inhibition and




Article Type: Research Article
Full Title: Moderate to severe acute pain disturbs motor cortex intracortical inhibition and
facilitation in orthopedic trauma patients: A TMS study
Short Title: Acute pain in orthopedic trauma disturbs motor cortex intracortical inhibition and
facilitation
Corresponding Author: Louis De Beaumont
Universite de Montreal
Montréal, CANADA
Keywords: Pain intensity;  primary motor cortex;  cortical excitability;  fracture;  transcranial
magnetic stimulation.
Abstract: Objective:   Primary motor (M1) cortical excitability alterations are involved in the
development and maintenance of chronic pain. Less is known about M1-cortical
excitability implications in the acute phase of an orthopedic trauma. This study aims to
assess acute M1-cortical excitability in patients with an isolated upper limb fracture
(IULF) in relation to pain intensity. 
Methods:   Eighty-four (56 IULF patients <14 days post-trauma and 28 healthy
controls). IULF patients were divided into two subgroups according to pain intensity
(mild versus moderate to severe pain). A single transcranial magnetic stimulation
(TMS) session was performed over M1 to compare groups on resting motor threshold
(rMT), short-intracortical inhibition (SICI), intracortical facilitation (ICF) and long-interval
cortical inhibition (LICI). 
Results:   Reduced SICI and ICF were found in IULF patients with moderate to severe
pain, whereas mild pain was not associated with M1 alterations. Age, sex, and time
since the accident had no influence on TMS measures.  
Discussion:   These findings show altered M1 in the context of acute moderate to
severe pain, suggesting early signs of altered GABAergic inhibitory and glutamatergic
facilitatory activities.













Response to Reviewers: Comment #1: In regard to contamination of SICI by SICF, I was not suggesting to use
AMT. The issue could have been accounted for by using a lower %RMT conditioning
stimulus. I understand why the authors would want to include the intensity commonly
tested within the existing literature, but inclusion of an additional, lower intensity,
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conditioning stimulus would have been very feasible. At the very least, the possibility of
SICF contamination should be addressed to some degree in the discussion.
Response to Comment #1: We have addressed this comment in the limitation section.
Comment #2: The authors did not address why they elected to retain outcomes of all
post-hoc comparisons in the figures, despite the fact that they’re reported in the text
(see comment 9).
Response to Comment #2: Our apologies. We have made the necessary changes and
removed all results from the post-hoc statistics.
Comment #3: Typos on line 224 (RMT criteria still refer to 0.5mV MEP, which should
be 0.05mv) and 243 (LICI stimuli referred to as subthreshold, should be
suprathreshold).
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Objective: Primary motor (M1) cortical excitability alterations are involved in the 30 
development and maintenance of chronic pain. Less is known about M1-cortical 31 
excitability implications in the acute phase of an orthopedic trauma. This study aims to 32 
assess acute M1-cortical excitability in patients with an isolated upper limb fracture 33 
(IULF) in relation to pain intensity.  34 
Methods: Eighty-four (56 IULF patients <14 days post-trauma and 28 healthy controls). 35 
IULF patients were divided into two subgroups according to pain intensity (mild versus 36 
moderate to severe pain). A single transcranial magnetic stimulation (TMS) session was 37 
performed over M1 to compare groups on resting motor threshold (rMT), short-38 
intracortical inhibition (SICI), intracortical facilitation (ICF), and long-interval cortical 39 
inhibition (LICI).  40 
Results: Reduced SICI and ICF were found in IULF patients with moderate to severe 41 
pain, whereas mild pain was not associated with M1 alterations. Age, sex, and time since 42 
the accident had no influence on TMS measures.   43 
Discussion: These findings show altered M1 in the context of acute moderate to severe 44 
pain, suggesting early signs of altered GABAergic inhibitory and glutamatergic 45 
facilitatory activities. 46 
 47 
 48 
  49 
 3 
Introduction  50 
Orthopedic trauma (OT) patients are routinely afflicted by pain and it is 51 
considered the most common and debilitating symptom reported among this population 52 
[1, 2]. Optimal pain control is an OT care priority as pain interferes with trauma recovery 53 
and affects outcome [3, 4].  54 
A growing body of research is currently focused on developing alternative pain 55 
management techniques to tackle the alarming drawbacks associated with current 56 
standards of care. Among these alternatives, transcranial magnetic stimulation (TMS) has 57 
gained attention in recent years for its dual role: 1) its ability to objectively assess pain 58 
mechanisms; and 2) its potential applicability in pain management. In chronic pain 59 
studies, the primary motor cortex (M1) commonly serves as the targeted brain region due 60 
to its connections with the nociceptive system and the known effect of pain on motor 61 
function [5, 6]. Despite some variability across TMS studies, there is extensive evidence 62 
of an altered balance between inhibitory and facilitatory circuits of M1 in various chronic 63 
pain conditions (i.e. fibromyalgia, neuropathic pain, complex regional pain syndrome, 64 
phantom limb pain, chronic orofacial pain) [7, 8]. These results highlight maladaptive 65 
plasticity within the motor system. M1-cortical excitability alterations have been 66 
associated with the severity of the clinical symptoms such as pain intensity, hyperalgesia, 67 
and allodynia [9, 10], pointing to the value of TMS as an objective tool that reflects 68 
functional alterations. Moreover, cortical excitability restoration through repetitive TMS 69 
(rTMS), a technique known to induce lasting modulation effects on brain activity through 70 
a multiple day session paradigm, has shown some efficacy in reducing the magnitude of 71 
pain, even in refractory chronic pain patients [11-16]. Overall, these results support the 72 
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role of cortical excitability on pain intensity in chronic pain patients and the potential 73 
clinical utility of TMS in pain management among this population. 74 
On the other hand, acute pain initiated by an OT, such as following a fracture, has 75 
received little to no attention, despite being highly prevalent. With 15% to 20% of all 76 
physician visits intended to address pain-related issues [17, 18], management of acute pain 77 
following OT still remains medically challenging [19-22]. Knowing that acute and chronic 78 
pain belong to the same continuum and that there is clear evidence of success in the use of 79 
rTMS in treating chronic pain, this technique could serve as a potential treatment tool in 80 
the early phase of fracture pain by tackling key elements of pain chronification. First, 81 
however, a better understanding of the involvement of M1-cortical excitability in acute 82 
pain is necessary.  83 
From a physiological point of view, it remains unclear whether motor cortical 84 
excitability impairments are expected in a context of acute pain following an OT. On one 85 
hand, neuroimaging studies suggest that possible disturbances within M1 only arise once 86 
chronic pain has developed, with acute and chronic pain exhibiting distinct and non-87 
overlapping brain activation patterns [23-27]. On the other hand, there is evidence 88 
supporting alterations of M1-cortical excitability during acute pain states. Indeed, 89 
Voscopoulos and Lema highlight early neuroplasticity involvement of GABA inhibitory 90 
interneurons following a peripheral insult, which may contribute to later transition to 91 
chronic pain [28]. In parallel, Pelletier and colleagues [29] suggested that pain intensity 92 
may act as the driving factor leading to M1-cortical excitability alterations rather than the 93 
state of chronic pain itself. This assumption was made by authors after obtaining similar 94 
M1 deficiency patterns across chronic pain conditions of various origins. Other TMS 95 
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studies also showed that pain of moderate to severe intensity (score 4 on numerical rating 96 
scale (NRS)) leads to greater motor cortex impairments [10]. The relationship between pain 97 
intensity in the acute state and its impact on cortical excitability parameters appears a 98 
relevant target of investigation.  99 
So far, very few studies have looked into the association between acute pain and 100 
M1-cortical excitability. These studies have mainly focused on experimental pain models 101 
in healthy subjects. More specifically, acute experimental pain of low-to-moderate 102 
intensity induces a generalized state of M1 inhibition, reflecting changes in both cortical 103 
and spinal motoneuronal excitability in healthy participants [30-35]. Findings suggest that 104 
acute experimental pain can modify cortical excitability of M1, but the result patterns 105 
obtained are different from chronic pain states. In parallel, rTMS studies have been shown 106 
effective in both alleviating acute experimental pain and modulating alterations in M1-107 
cortical excitability [36, 37]. Taken together, these findings show that M1 alterations can 108 
occur in the context of acute pain and that rTMS over M1 can successfully modulate 109 
nociceptive afferent information and restore M1 alterations, even for transient pain 110 
sensation in healthy controls. However, due to the subjective nature of pain sensation along 111 
with intrinsic differences in pain characteristics across conditions and individuals, 112 
translation between experimental pain model and clinical pain following an OT is limited. 113 
Therefore, if we are to consider the potential clinical utility of rTMS in alleviating acute 114 
pain, studies need to be conducted in a clinical population. 115 
This study therefore aims to assess acute M1-cortical excitability functioning 116 
through well-established TMS paradigms according to pain intensity in patients who are in 117 
the acute pain phase following an isolated upper limb fracture (IULF). We hypothesize that 118 
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M1-cortical excitability alterations will be found in patients with higher levels of pain 119 
compared to healthy controls and to IULF patients with mild pain.  120 
Materials and Methods  121 
This work was approved by the Hôpital du Sacré-Coeur de Montréal' Ethics Committee 122 
(Approval number: 2017-1328). A written consent was obtained by all participating 123 
subjects prior to the start of the study. A financial compensation was given to all subjects 124 
for their participation. 125 
Participants 126 
Our sample included 1) patients who have suffered from an isolated upper limb fracture 127 
(IULF) and 2) healthy controls. Patients with an IULF were initially recruited from 128 
various orthopedic clinics affiliated to a Level 1 Trauma Hospital. To be included in the 129 
study, patients had to be aged between 18 and 60 years old and have sustained an IULF 130 
(one fractured bone from upper body extremities) within 14 days post-injury. 131 
Recruitment of IULF patients took place on the day of the first medical appointment at 132 
the orthopedic trauma clinic with the orthopedic surgeon. Testing was conducted within 133 
24 hours post-medical consultation. All testing measures had to be completed prior to 134 
surgical procedures (if any) given the known impact of surgery on increased 135 
inflammatory response and pain perception [38]. Exclusion criteria consisted of a history 136 
of traumatic brain injuries, a diagnosis of and/or a treatment for a psychiatric condition in 137 
the last ten years, musculoskeletal deficits, neurological conditions (i.e. epilepsy), chronic 138 
conditions (cancer, uncontrolled diabetes, cardiovascular illness, high blood pressure), 139 
the use of central nervous system-active medication (hypnotics, antipsychotics, 140 
antidepressant, acetylcholinesterase inhibitor, anticonvulsant), history of alcohol and/or 141 
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substance abuse, acute medical complications (concomitant traumatic brain injury, 142 
neurological damage, etc.), and being intoxicated at the time of the accident and/or at the 143 
emergency visit. Of note, IULF patients were not restrained from using analgesic 144 
medication (acetaminophen, ibuprofen, opioids, etc.) during testing to assure comfort and 145 
to avoid interfering with pain management.  146 
 147 
The control group consisted of healthy right-handed adults recruited through various 148 
social media platforms. As per usual practice in conducting M1 TMS studies, only right-149 
handed control participants were selected as stimulation over non-dominant M1 has been 150 
associated with accentuated within-subject variability [39, 40]. They self-reported to be 151 
free of all previously mentioned exclusion criteria.    152 
Study participants were also screened for TMS tolerability and safety [41].  153 
 154 
Assessment measures  155 
Total assessment procedures (including consent) were conducted over a single, 90-minute 156 
session. First, participants were invited to complete self-administered questionnaires to 157 
gather demographic information and clinical outcome measures (pain intensity and 158 
functional disability indices). More specifically, demographic data such as age, sex, and 159 
level of education were documented and used to ensure homogeneity between groups.  160 
 161 
Clinical outcome: Pain intensity and functional disability indices 162 
 To assess the perceived level of pain at the time of testing, the numerical rating scale 163 
(NRS), a routinely used standardized generic unidimensional clinical pain questionnaire, 164 
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was administered [42, 43]. To complete the NRS, participants had to circle a number that 165 
best fit their current level of pain on the 11-point pain intensity scale, with numbers 166 
ranging from 0 (“no pain”) to 10 (“worst possible pain”). In order to test the hypothesized 167 
impact of acute pain intensity on M1 cortical excitability, IULF patients were divided 168 
into two distinct groups according to NRS score: 1) IULF patients who self-reported 169 
moderate to severe pain intensity (NRS 4 out of 10); 2) IULF patients with mild pain 170 
intensity (NRS <4). The cut-off pain intensity scores are based on previous pain studies 171 
[10, 44, 45]. 172 
The disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire was used as a tool 173 
to assess an individual’s ability to perform common specific everyday activities relying 174 
on upper extremity limbs [46, 47]. This questionnaire consists of 30 items, including 6 175 
that are symptom-related and 24 that are function-related, where patients were asked to 176 
rate the level of disability on each activity as experienced since their accident. Continuum 177 
of scores on this questionnaire varies between 0 (no disability) and 100 (extreme 178 
difficulty).  179 
 180 
Comprehensive assessment of M1 cortical excitability using TMS.  181 
To assess M1 cortical excitability, a TMS figure-of-eight stimulation coil (80mm wing 182 
diameter), attached to a Bistim2 Magstim transcranial magnetic stimulators (Magstim 183 
Company, Whitland, Dyfed, UK), was used. The TMS-coil was positioned flat on the 184 
scalp over M1 at a 45 angle from the mid-sagittal line, with its handle pointing 185 
backwards. In the IULF group, the TMS coil was positioned over M1 contralaterally to 186 
the injury, whereas in the control group, the TMS-coil was systematically positioned over 187 
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the dominant left hemisphere. Motor evoked potentials (MEP) recordings from the 188 
abductor pollicis brevis (APB) was performed using three electrodes positioned over the 189 
belly of the target muscle (active electrode (+)), between the distal and proximal 190 
interphalangeal joints of the index (reference (-)), and on the forearm (ground). Optimal 191 
stimulation site was determined based on the coil position which evoked highest peak-to-192 
peak MEP amplitudes from the target muscle. We used a 3D tracking system (Northern 193 
Digital Instruments, Waterloo, Canada) to ensure accurate and consistent TMS coil 194 
positioning on the targeted site.  195 
 196 
Various well-established TMS protocols were conducted to investigate M1 excitatory and 197 
inhibitory mechanisms using single and paired-pulse paradigms. Single pulse magnetic 198 
stimulations were first used to establish the resting motor threshold (rMT), i.e. the 199 
minimal stimulation intensity needed to elicit a MEP of at least 0.05mV in five out of ten 200 
trials [48]. An interstimulus interval, varying from 8 to 10 seconds, was applied to control 201 
for possible residual effects of TMS stimulation on M1 activity [49]. The sequence of 202 
stimulation intensity was randomly generated by a computer. Short intra-cortical-203 
inhibition (SICI) and facilitation (ICF) were measured via a classic paired-pulse 204 
paradigm [50, 51]. The latter protocol involves the application of two successive TMS 205 
pulses, the first pulse set at 80% of the rMT intensity (subthreshold; conditioning 206 
stimulus) and the second pulse set at 120% of the rMT (suprathreshold; test stimulus) 207 
separated by an interstimulus interval (ISI) of a predetermined duration [50]. To test for 208 
SICI, a measure attributed to GABAA interneurons and receptors activity [52], one 209 
sequence of 10 paired-pulse stimulations was completed with an ISI set at 3ms. To test 210 
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for ICF, one sequence of 10 stimulations was performed with ISI set at 12ms. Measure of 211 
ICF is thought to be mediated by excitatory glutamatergic interneurons and N-methyl-D-212 
aspartate (NMDA) receptors [52-56]. Results of SICI and ICF are expressed as 213 
percentage ratios of MEP amplitudes. These ratios represent the mean MEP amplitude of 214 
paired TMS over the mean MEP amplitude of the test stimuli baseline measurement (10 215 
single magnetic pulses set at 120% rMT). Therefore, high SICI values reflect a lack of 216 
intracortical inhibition, whereas a low value ICF corresponds to a lack of intracortical 217 
facilitation. Finally, we measured long-interval cortical inhibition (LICI) through paired-218 
pulse TMS of identical suprathreshold intensity (i.e. 120% rMT) with an ISI of 100ms. 219 
The first pulse corresponded to the conditioning stimulus whereas the second pulse was 220 
the test stimulus. LICI is primarily known to be mediated by GABAB receptors [57, 58]. 221 
To calculate LICI, we used the percentage ratio between the mean peak-to-peak MEP 222 
amplitude of the test stimulus response (TSR) and the mean peak-to-peak MEP amplitude 223 
of the conditioning stimulus response (CSR) expressed as: mean (TSR)/mean(CSR). 224 
Statistics 225 
Statistical analyses were performed using IBM SPSS Statistics software version 25 226 
(Armonk, NY, United States). The Shapiro-Wilks test was used to determine the 227 
normality of the data. Parametric and nonparametric tests were performed, where 228 
appropriate, with a -level fixed at 0.05. Descriptive analyses were used to characterize 229 
and compare the three groups (1- IULF patients with NRS4; 2- IULF patients with 230 
NRS<4; 3- healthy controls) in our study sample. Results from descriptive analyses are 231 
expressed as means, standard deviation (SD), and percentages. We used a Student’s t-test 232 
or a Mann-Whitney U test to investigate group differences on TMS measures. An 233 
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analysis of variance (ANOVA) or the Kruskal-Wallis test were also used where 234 
appropriate. Pearson and Spearman’s correlation analysis were also computed to assess 235 
the relationship between functional disability outcomes and the other outcome measures 236 
of interest (pain intensity and TMS measures). We corrected for multiple comparisons 237 
using False Discovery Rate (FDR) where appropriate.  Post-hoc analyses were conducted 238 
to control for the effect of within-group variability of stimulated hemispheres across 239 
IULF patients on TMS measures as it varied according to the injury location (left or 240 
right). Therefore, we elected to create subgroups as follow: IULF patients stimulated over 241 
the left hemisphere (IULF with left-M1) and IULF patients stimulated on the right 242 
hemisphere (IULF with right-M1). Lastly, a post-hoc linear regression analysis was 243 
computed to assess which independent variables between pain intensity (NRS score from 244 
0-10) and the number of days between the accident and testing (independent variable) 245 
best predict significant changes in M1-cortical excitability (dependent variable) in IULF 246 
patients.  247 
 248 
Results  249 
Demographic information 250 
A total of 84 subjects took part in the current study, of which 56 had suffered an IULF 251 
(23 females; mean age: 39.41 years old) and 28 were healthy controls (17 females; mean 252 
age: 34.93). Two subgroups of IULF patients were formed according to pain intensity: 253 
Twenty-five IULF individuals met the criteria for moderate to severe pain (NRS 4), 254 
whereas 31 IULF subjects were classified as having mild pain (NRS <4). Age (H=3.89; 255 
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p=0.14) and sex (F(81)=3.76; p=0.15) did not differ between groups, whereas the level of 256 
education (F(81)=3.95; p=0.02) and the time elapsed between the accident and testing  257 
(U=225.50; p=0.01) were statistically different across groups. More specifically, IULF 258 
patients with NRS4 were tested on average 4.48 (SD=3.50) days post-accident 259 
compared to 7.55 (SD=4.45) days for IULF patients with NRS<4. Spearman’s 260 
correlational analyses revealed a strong association between pain intensity and the extent 261 
of functional disability as measured through the DASH questionnaire (rs=0.76; p<0.001). 262 
Refer to tables 1-2 for additional descriptive information regarding study sample and 263 
fracture distribution among IULF patients.  264 
 265 
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 267 
Table 2. Fracture distribution among IULF patients 268 
Type of fracture N (subjects [%]) 
- Radial head 11(19.64) 
- Collarbone 8 (14.29) 
- Humerus 9 (16.07) 
- Distal radius 21 (37.50) 
- Scaphoid 4 (7.14) 
- Scapula 1 (1.79) 
- Ulna 2 (3.57) 
 269 
 Group differences on M1-cortical excitability measures in relation 270 
to pain threshold 271 
Resting Motor Threshold (rMT) 272 
Mann-Whitney U test revealed that IULF patients with NRS4 did not statistically differ 273 
from IULF patients with NRS<4 (U=324.50; p=0.54) and healthy controls (U=323.50; 274 
p=0.82) on rMT. Similarly, IULF patients with NRS<4 showed equivalent rMT measures 275 
as healthy controls (U=365.00; p=0.39). See Fig 1A.  276 
Fig 1. Groups differences on TMS measures 277 
 278 
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MEPs test stimulus intensity 279 
MEPs of the test stimulus used to measure SICI and ICF were equivalent between 280 
groups. Indeed, IULF patients with NRS4 did not statistically differ from IULF patients 281 
with NRS<4 (U=336.00; p=0.40) and healthy controls (U=304.00; p=0.41). Moreover, 282 
IULF patients with NRS<4 and healthy controls were comparable (U=431.00; p=0.96). 283 
See Fig 1B. 284 
Short intra-cortical inhibition (SICI) 285 
Results showed that IULF patients with NRS 4 statistically differed from healthy 286 
controls (U=202.00; p<0.01), with NRS 4 IULF patients exhibiting reduced short-287 
intracortical inhibition of M1. A tendency toward reduced short-intracortical inhibition 288 
was found in IULF patients with NRS 4 compared to IULF patients with NRS <4, but 289 
the difference failed to reach significance (U=282.50; p=0.08),. Lastly, IULF patients 290 
with NRS<4 and healthy controls showed similar SICI (U=383.00; p=0.44). See Fig 1C. 291 
We then conducted a post-hoc linear regression to assess the contribution of both pain 292 
intensity and delay between the accident and testing on SICI disinhibition. Data shows 293 
that pain intensity at the time of testing significantly predicted SICI disinhibition and 294 
explained 29% of the variance (-coefficient = 0.29; p=0.05), whereas the delay between 295 
the accident and testing poorly predicted SICI disinhibition (-coefficient= 0.07; 0.63).  296 
 297 
 Intra-cortical facilitation (ICF)  298 
IULF patients with NRS4 exhibited a significantly reduced ICF (t(54)=2.44; p=0.02) 299 
relative to IULF patients with NRS<4. IULF patients with NRS4 (t(51)=-1.63; p=0.11) 300 
and IULF with NRS<4 (t(57)=0.37; p=0.71) did not statistically differ from healthy 301 
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controls. See Fig 1D. Results from a post-hoc linear regression showed that pain intensity 302 
significantly predicted altered ICF (-coefficient=-0.30; p=0.04), accounting for 30% of 303 
the variance, whereas delay between the accident and testing (-coefficient=-0.02; 304 
p=0.87) poorly predicted altered ICF. 305 
 306 
Long-interval cortical inhibition (LICI) 307 
IULF patients with NRS4 had similar LICI values compared to IULF patients with 308 
NRS<4 (U=339.00; p=0.42) and healthy controls (U=324.00; p=0.64). IULF patients 309 
with NRS<4 and healthy controls were also equivalent on LICI (U=405.00; p=0.66). See 310 
Fig 1E.  311 
 312 
Post-hoc analyses controlling for the side of the stimulated 313 
hemisphere in IULF patients 314 
To investigate if the stimulated hemisphere had an impact on cortical excitability 315 
measures, IULF patients were stratified into two distinct groups: IULF patients 316 
stimulated on the left M1 and IULF patients stimulated on the right M1. Demographic 317 
data such as age (U=296.00; p=0.12), sex (X2(1)=0.002; p=0.96), education level 318 
(t(54)=1.17; p=0.25), and the timing of testing in relation to the accident (U=339.50; 319 
p=0.39) were similar across groups (see table 3). Lastly, there was no between-group 320 
difference in regard to pain intensity (U=297.50; p=0.12).  321 
 322 
Table 3. Descriptive characteristics of IULF patients according to the stimulated 323 
hemisphere  324 
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Results of the 








U= 296.00 0.12 
Sex (female [%]) 
11 (41%) 12 (43%) 








t= 1.17 0.25 
Number of days 




5.67 (3.92) 6.66 (4.65) 
U= 339.50 0.39 
NRS Actual pain (SD) 
2.81 (2.83) 3.59 (2.13) 
U= 297.50 0.12 
 326 
 Group differences on M1-cortical excitability measures in relation to M1 327 
stimulation side 328 
None of the TMS measures differed across IULF patients according to the stimulated 329 
hemisphere [rMT (U=359.00; p=0.93); SICI (U= 377.00; p=0.81); ICF (t(54)=-0.44; 330 
p=0.6); LICI (U= 361.50; p=0.62)]. See Fig 2A-D.  331 
 332 
Relationship between cortical excitability measures and functional disability 333 
outcomes 334 
The DASH questionnaire was used to investigate the relationship between functional 335 
disability outcomes and cortical excitability parameters. Only IULF subjects were 336 
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included in this analysis, whereas healthy controls were excluded. Results show that the 337 
DASH score was strongly associated with SICI (Rs=0.37; p=0.006), whereas no 338 
correlation was found with ICF (r= -0.11; p=0.46), LICI (Rs=-0.06; p=0.67), and rMT 339 
(Rs= 0.18; p=0.22).  340 
 341 
Fig 2A-D. Between IULF-group differences on TMS measures stratified according 342 
to the stimulated hemisphere.  343 
 344 
 345 
Discussion  346 
 347 
This study provides new insights into the involvement of the primary motor cortex in the 348 
early phase of recovery (<14 days post-trauma) following an IULF through various TMS 349 
protocols assessing M1-cortical excitability. More precisely, results suggest a significant 350 
decrease in intracortical inhibition and facilitation in IULF patients over the cortical 351 
representation of the fractured bone. These neurophysiological alterations were only 352 
observed in IULF patients with pain of moderate to severe intensity (NRS 4), whereas 353 
IULF patients with mild pain did not differ from healthy controls. Furthermore, this study 354 
highlights that the time elapsed between the accident and testing within the first 14 days 355 
of the accident, as well as the stimulated hemisphere, do not influence any of the primary 356 
motor cortex excitability measures. On the contrary, pain intensity emerges as the main 357 
factor explaining acute abnormalities of M1 excitability in IULF patients relative to a 358 
healthy cohort of similar age, sex distribution, and education level. To the best of our 359 
knowledge, this is the first study to investigate M1-cortical excitability in acute pain 360 
following an isolated upper limb fracture.  361 
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This study suggests a state of disinhibition through reduced SICI, a TMS measure 362 
that is robustly associated to GABAA receptors activity [52], but only in patients with 363 
moderate to severe pain intensity (NRS 4). Moreover, the extent of SICI disruption was 364 
strongly associated with functional disability scores (DASH). Current findings highlight 365 
possible resemblance across pain states, as SICI disturbances are also found in various 366 
chronic pain conditions [7, 59-61]. A reduction of GABAergic inhibition has been shown 367 
to play a prominent role in chronic pain development and in pain maintenance [62]. It is 368 
therefore no surprise that GABA receptor agonists have proven effective as an analgesic 369 
agent, but important side effects limit its long-term use [63, 64]. Identification of a state 370 
of disinhibition at such an early stage of recovery in patients with a fracture is of 371 
particular clinical relevance in this population since high initial pain is considered a risk 372 
factor for chronic pain development [65]. These results may further our understanding as 373 
to why high levels of pain in the acute phase is considered a risk factor for chronic pain. 374 
Indeed, patients with moderate to severe pain (NRS 4) are affected by disrupted 375 
GABAergic inhibition within the first few days post-trauma, which may hypothetically 376 
contribute to CNS’ vulnerability to pain chronification.  377 
Of note, current findings diverge from results found in experimental acute pain 378 
studies. Experimentally induced pain in healthy controls shows an increase in M1 379 
intracortical inhibition whereas the current study found a decrease in inhibition in IULF 380 
patients presenting with moderate to severe acute pain (NRS 4). Increased SICI in acute 381 
experimental pain has been suggested as an adaptation strategy to prevent CNS 382 
reorganization [32]. Given the reverse pattern of M1 disinhibition in IULF patients, one 383 
should investigate whether moderate to severe pain symptoms in the latter clinical 384 
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population may facilitate lasting CNS reorganization through sustained activation of 385 
plasticity mechanisms. One reason for the discrepancies in SICI findings between 386 
experimental and acute clinical pain could be that fracture pain involves multiple 387 
physiological mechanisms that cannot be replicated in a human experimental setting. For 388 
example, the physiological cascade following tissue injury and bone fracture alone, 389 
including an acute inflammatory response, can modulate brain excitability [66] and 390 
impair GABAergic and glutamatergic activities [67]. Future studies combining both 391 
experimental paradigms in a healthy cohort and clinical pain in OT patients are warranted 392 
if we are to investigate the mechanisms involved and to restrict results discrepancy due to 393 
possible methodological variabilities.  394 
Current results also reveal alterations of intracortical facilitation in IULF patients 395 
with moderate to severe pain (NRS 4), a measure traditionally considered to be 396 
mediated by glutamatergic facilitatory transmission [52-56]. The finding that both ICF 397 
and SICI are reduced may appear counterintuitive from a physiological standpoint. 398 
However, physiological underpinnings of TMS-induced ICF effects have been the subject 399 
of ongoing debate, as some evidence suggest that the latter reflects an overlap between 400 
inhibitory and excitatory mechanisms [54]. Along those lines, pharmacological studies 401 
have shown that both NMDA receptors antagonists (such as dextromethorphan and 402 
memantine) as well as GABAA agonists can modulate ICF. In parallel, some TMS and 403 
chronic pain studies have shown reduced ICF, but this was mainly found in patients with 404 
fibromyalgia [11, 61]. Additional factors relevant to the orthopedic population could also 405 
account for current study findings. For example, other types of pain (muscle pain, bone 406 
pain, etc.) and inflammatory response can influence the balance between inhibitory and 407 
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facilitatory mechanisms [66, 67]. Moreover, limb disuse may also affect brain plasticity 408 
due to reduced sensorimotor input and output [68-70]. 409 
Current findings support work from Pelletier and colleagues [29] suggesting that 410 
pain intensity, rather than pain state, appears to be linked to the extent of motor cortex 411 
excitability alterations. As such, patients who reported moderate to severe pain (NRS 4) 412 
showed accentuated SICI and ICF alterations as compared to patients with mild pain 413 
levels who showed a similar M1 excitability profile to healthy controls. This is 414 
particularly interesting as results from the current study showed that patients with higher 415 
pain levels also reported greater functional disability. Therefore, study findings are not 416 
only consistent with the notion that high initial pain is a good predictor for chronic pain, 417 
but it also argues that altered cortical excitability of M1 could contribute to underlying 418 
mechanisms of pain chronification following a fracture [71, 72].  419 
Although a similar M1-cortical excitability profile may emerge between acute and 420 
chronic injury phases, the involvement of the CNS may be different. One should bear in 421 
mind that altered SICI and ICF in acute pain do not necessarily indicate permanent CNS 422 
reorganization. Although speculative, acute changes in M1-cortical excitability could also 423 
reflect the intensity of the nociceptive afferent originating from the periphery. It should 424 
be noted that the group of patients reporting moderate to severe (NRS 4) pain levels 425 
who also exhibited altered M1-cortical excitability were tested at a significantly shorter 426 
delay following the accident relative to patients who reported mild levels of pain. One 427 
cannot exclude the possibility that alterations of M1-cortical excitability within the first 428 
few days of the injury could have subsided as pain intensity is expected to reduce with 429 
additional time to recover. However, results from linear regressions, used to delimitate 430 
 21 
the weight of the timing of testing in relation to the accident and pain intensity on altered 431 
M1-cortical excitability, showed that pain intensity best predicted altered intracortical 432 
inhibition and facilitation, whereas timing of testing had no impact within that short 14-433 
day time frame. Longitudinal follow-ups are nonetheless needed to investigate 434 
longitudinal changes of TMS-induced M1 excitability measurements in relation with pain 435 
stages, particularly during the transition from acute to chronic pain. 436 
LICI, another measure reflecting GABAB receptors inhibition, was found to be 437 
unrelated to reported pain intensity following a peripheral injury. In a recent review, 438 
authors only found scarce evidence of the involvement of LICI alterations in various 439 
chronic pain conditions [7], either suggesting that GABAB receptors remain intact or that 440 
the latter measure may be less sensitive to pain states. It would still appear relevant to 441 
include other TMS paradigms known to measure GABAA and GABAB receptors, namely 442 
short-afferent inhibition (SAI), long-afferent inhibition (LAI), and the cortical silent 443 
period (CSP) in the context of future studies [54, 73]. This would allow us to deepen our 444 
understanding of the involvement of acute pain on the GABAergic inhibitory system in 445 
IULF patients.  446 
Given the known durable effects of multisession rTMS protocols on M1-cortical 447 
excitability and on pain reduction, rTMS appears as a highly relevant intervention avenue 448 
for the IULF population. Acute rTMS application should be considered as an intervention 449 
option as it may provide analgesic effects to suffering patients, in addition to possibly 450 
tackling cortical excitability changes associated with pain chronification.  451 
One limitation to the current study is the use of a single TMS session to 452 
investigate M1-cortical excitability implications in the acute phase of an IULF in relation 453 
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to pain intensity. Longitudinal studies are needed among this population to further 454 
explore the effects of early M1-cortical excitability dysregulations on recovery. This 455 
would provide valuable insights as to whether acute altered M1-cortical excitability is a 456 
predictor of pain chronification. Secondly, this study uses limited, but well established, 457 
TMS parameters. Still, it should be considered that TMS parameters vary greatly across 458 
studies (e.g. ISI, test and conditioned stimuli intensity), surely contributing to result 459 
variability found in the literature. This poses a challenge for researchers to establish the 460 
most sensitive and specific TMS parameters. In the context of the present study, it should 461 
be considered that previous studies have highlighted possible contamination by short-462 
afferent cortical facilitation (SICF) in SICI according to the TMS parameters used [74, 463 
75]. Although the present study uses parameters from previously published studies, SICF 464 
contamination cannot be excluded. It would be important to account for these findings in 465 
future studies. Moreover, the use of additional TMS paradigms (SAI, LAI, CSP) as well 466 
as an objective measure of pain, such as conditioned pain modulation [76, 77], would be 467 
highly relevant in the context of future studies to draw a thorough physiological profile of 468 
ascending and descending tracks in IULF patients with moderate to severe pain (NRS 469 
4). Thirdly, since the initial medical consultations varied across IULF individuals, 470 
timing of testing post-accident was not equivalent within the IULF group. Although post-471 
hoc analyses showed that this factor did not influence TMS outcomes, future studies 472 
should, to the extent possible, assess patients at a fixed day since the physiological 473 
cascade following the injury is rapidly evolving. Fourthly, pain medication usage and 474 
dosage at the time of testing were not restrained in IULF patients, possibly leading to 475 
interindividual variability among the sample. Effects of analgesics medication on cortical 476 
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excitability measures cannot be excluded although very scarce evidence exists. One study 477 
showed that acetaminophen can increase MEP, which facilitates the inhibition of voltage-478 
gated calcium and sodium currents [78]. In this case, and in relation with current study 479 
results showing decreased intracortical inhibition, acetaminophen usage among study 480 
sample could have masked cortical excitability deficiencies. As for opioid analgesics, 481 
only one study mentioned that fentanyl does not alter MEP amplitudes [56], a drug that is 482 
rarely used to treat acute pain. Fifthly, future studies should also account for additional 483 
factors, such as the inflammatory cascade (pro-inflammatory cytokines levels) and 484 
genetic predisposition, as they are known to impact pain intensity and M1-cortical 485 
excitability measures [79-82]. Accounting for such factors would be beneficial to develop 486 
tailored interventions for the IULF population. Sixthly, the stimulated hemisphere (right 487 
or left M1) varied in IULF patients according to the injured side. This factor was 488 
controlled for in IULF patients and no differences were found. On the other hand, all 489 
healthy controls were right-handed and were stimulated on the left-M1, which 490 
corresponds to the dominant hemisphere as per optimal TMS guidelines. Since no 491 
differences were found among the clinical sample, we elected to follow the TMS 492 
guidelines in the healthy sample. Finally, evidence show that reduced use of limb (limb 493 
immobilization) can indeed lead to brain changes (cortical thickness, cortical excitability, 494 
etc.) in the motor cortex due to reduced sensory input/sensorimotor deprivation [68-70, 495 
83]. We can by no mean exclude this factor entirely, but a few points should be 496 
considered. First, IULF patients were tested very early post-injury, leaving less time for 497 
measurable brain changes. Second, statistical analyses show that the number of days 498 
between testing and the accident (possible indicator of reduced limb use) is not associated 499 
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with alterations in cortical excitability measures. Lastly, IULF patients who showed most 500 
cortical excitability deficiencies were actually tested within shorter delays of accident 501 
(NRS >4 group), leaving less time, compared to the other IULF group (NRS<4), for 502 
cortical reorganization due to limb immobilization.   503 
Conclusions 504 
In conclusion, this is the first study to investigate M1 cortical excitability involvement in 505 
an orthopedic trauma population suffering from acute pain. Current results show early 506 
signs of altered GABAergic inhibitory and glutamatergic facilitatory activities in patients 507 
with pain of moderate to severe intensity (NRS 4). These findings may bear major 508 
clinical significance as this population is vulnerable to chronic pain development. Early 509 
detection of at-risk patients could guide proactive intervention aiming to reduce the 510 
likelihood of an unsuccessful recovery in this population, leading to a pathological 511 
condition. This study also highlights that acute application of rTMS may reveal 512 
promising in alleviating pain symptoms among this population and may have 513 
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Figure 1C. Between group comparison on SICI 
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Objective: Primary motor (M1) cortical excitability alterations are involved in the 30 
development and maintenance of chronic pain. Less is known about M1-cortical 31 
excitability implications in the acute phase of an orthopedic trauma. This study aims to 32 
assess acute M1-cortical excitability in patients with an isolated upper limb fracture 33 
(IULF) in relation to pain intensity.  34 
Methods: Eighty-four (56 IULF patients <14 days post-trauma and 28 healthy controls). 35 
IULF patients were divided into two subgroups according to pain intensity (mild versus 36 
moderate to severe pain). A single transcranial magnetic stimulation (TMS) session was 37 
performed over M1 to compare groups on resting motor threshold (rMT), short-38 
intracortical inhibition (SICI), intracortical facilitation (ICF), and long-interval cortical 39 
inhibition (LICI).  40 
Results: Reduced SICI and ICF were found in IULF patients with moderate to severe 41 
pain, whereas mild pain was not associated with M1 alterations. Age, sex, and time since 42 
the accident had no influence on TMS measures.   43 
Discussion: These findings show altered M1 in the context of acute moderate to severe 44 
pain, suggesting early signs of altered GABAergic inhibitory and glutamatergic 45 
facilitatory activities. 46 
 47 
 48 
  49 
 3 
Introduction  50 
Orthopedic trauma (OT) patients are routinely afflicted by pain and it is 51 
considered the most common and debilitating symptom reported among this population 52 
[1, 2]. Optimal pain control is an OT care priority as pain interferes with trauma recovery 53 
and affects outcome [3, 4].  54 
A growing body of research is currently focused on developing alternative pain 55 
management techniques to tackle the alarming drawbacks associated with current 56 
standards of care. Among these alternatives, transcranial magnetic stimulation (TMS) has 57 
gained attention in recent years for its dual role: 1) its ability to objectively assess pain 58 
mechanisms; and 2) its potential applicability in pain management. In chronic pain 59 
studies, the primary motor cortex (M1) commonly serves as the targeted brain region due 60 
to its connections with the nociceptive system and the known effect of pain on motor 61 
function [5, 6]. Despite some variability across TMS studies, there is extensive evidence 62 
of an altered balance between inhibitory and facilitatory circuits of M1 in various chronic 63 
pain conditions (i.e. fibromyalgia, neuropathic pain, complex regional pain syndrome, 64 
phantom limb pain, chronic orofacial pain) [7, 8]. These results highlight maladaptive 65 
plasticity within the motor system. M1-cortical excitability alterations have been 66 
associated with the severity of the clinical symptoms such as pain intensity, hyperalgesia, 67 
and allodynia [9, 10], pointing to the value of TMS as an objective tool that reflects 68 
functional alterations. Moreover, cortical excitability restoration through repetitive TMS 69 
(rTMS), a technique known to induce lasting modulation effects on brain activity through 70 
a multiple day session paradigm, has shown some efficacy in reducing the magnitude of 71 
pain, even in refractory chronic pain patients [11-16]. Overall, these results support the 72 
 4 
role of cortical excitability on pain intensity in chronic pain patients and the potential 73 
clinical utility of TMS in pain management among this population. 74 
On the other hand, acute pain initiated by an OT, such as following a fracture, has 75 
received little to no attention, despite being highly prevalent. With 15% to 20% of all 76 
physician visits intended to address pain-related issues [17, 18], management of acute pain 77 
following OT still remains medically challenging [19-22]. Knowing that acute and chronic 78 
pain belong to the same continuum and that there is clear evidence of success in the use of 79 
rTMS in treating chronic pain, this technique could serve as a potential treatment tool in 80 
the early phase of fracture pain by tackling key elements of pain chronification. First, 81 
however, a better understanding of the involvement of M1-cortical excitability in acute 82 
pain is necessary.  83 
From a physiological point of view, it remains unclear whether motor cortical 84 
excitability impairments are expected in a context of acute pain following an OT. On one 85 
hand, neuroimaging studies suggest that possible disturbances within M1 only arise once 86 
chronic pain has developed, with acute and chronic pain exhibiting distinct and non-87 
overlapping brain activation patterns [23-27]. On the other hand, there is evidence 88 
supporting alterations of M1-cortical excitability during acute pain states. Indeed, 89 
Voscopoulos and Lema highlight early neuroplasticity involvement of GABA inhibitory 90 
interneurons following a peripheral insult, which may contribute to later transition to 91 
chronic pain [28]. In parallel, Pelletier and colleagues [29] suggested that pain intensity 92 
may act as the driving factor leading to M1-cortical excitability alterations rather than the 93 
state of chronic pain itself. This assumption was made by authors after obtaining similar 94 
M1 deficiency patterns across chronic pain conditions of various origins. Other TMS 95 
 5 
studies also showed that pain of moderate to severe intensity (score 4 on numerical rating 96 
scale (NRS)) leads to greater motor cortex impairments [10]. The relationship between pain 97 
intensity in the acute state and its impact on cortical excitability parameters appears a 98 
relevant target of investigation.  99 
So far, very few studies have looked into the association between acute pain and 100 
M1-cortical excitability. These studies have mainly focused on experimental pain models 101 
in healthy subjects. More specifically, acute experimental pain of low-to-moderate 102 
intensity induces a generalized state of M1 inhibition, reflecting changes in both cortical 103 
and spinal motoneuronal excitability in healthy participants [30-35]. Findings suggest that 104 
acute experimental pain can modify cortical excitability of M1, but the result patterns 105 
obtained are different from chronic pain states. In parallel, rTMS studies have been shown 106 
effective in both alleviating acute experimental pain and modulating alterations in M1-107 
cortical excitability [36, 37]. Taken together, these findings show that M1 alterations can 108 
occur in the context of acute pain and that rTMS over M1 can successfully modulate 109 
nociceptive afferent information and restore M1 alterations, even for transient pain 110 
sensation in healthy controls. However, due to the subjective nature of pain sensation along 111 
with intrinsic differences in pain characteristics across conditions and individuals, 112 
translation between experimental pain model and clinical pain following an OT is limited. 113 
Therefore, if we are to consider the potential clinical utility of rTMS in alleviating acute 114 
pain, studies need to be conducted in a clinical population. 115 
This study therefore aims to assess acute M1-cortical excitability functioning 116 
through well-established TMS paradigms according to pain intensity in patients who are in 117 
the acute pain phase following an isolated upper limb fracture (IULF). We hypothesize that 118 
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M1-cortical excitability alterations will be found in patients with higher levels of pain 119 
compared to healthy controls and to IULF patients with mild pain.  120 
Materials and Methods  121 
This work was approved by the Hôpital du Sacré-Coeur de Montréal' Ethics Committee 122 
(Approval number: 2017-1328). A written consent was obtained by all participating 123 
subjects prior to the start of the study. A financial compensation was given to all subjects 124 
for their participation. 125 
Participants 126 
Our sample included 1) patients who have suffered from an isolated upper limb fracture 127 
(IULF) and 2) healthy controls. Patients with an IULF were initially recruited from 128 
various orthopedic clinics affiliated to a Level 1 Trauma Hospital. To be included in the 129 
study, patients had to be aged between 18 and 60 years old and have sustained an IULF 130 
(one fractured bone from upper body extremities) within 14 days post-injury. 131 
Recruitment of IULF patients took place on the day of the first medical appointment at 132 
the orthopedic trauma clinic with the orthopedic surgeon. Testing was conducted within 133 
24 hours post-medical consultation. All testing measures had to be completed prior to 134 
surgical procedures (if any) given the known impact of surgery on increased 135 
inflammatory response and pain perception [38]. Exclusion criteria consisted of a history 136 
of traumatic brain injuries, a diagnosis of and/or a treatment for a psychiatric condition in 137 
the last ten years, musculoskeletal deficits, neurological conditions (i.e. epilepsy), chronic 138 
conditions (cancer, uncontrolled diabetes, cardiovascular illness, high blood pressure), 139 
the use of central nervous system-active medication (hypnotics, antipsychotics, 140 
antidepressant, acetylcholinesterase inhibitor, anticonvulsant), history of alcohol and/or 141 
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substance abuse, acute medical complications (concomitant traumatic brain injury, 142 
neurological damage, etc.), and being intoxicated at the time of the accident and/or at the 143 
emergency visit. Of note, IULF patients were not restrained from using analgesic 144 
medication (acetaminophen, ibuprofen, opioids, etc.) during testing to assure comfort and 145 
to avoid interfering with pain management.  146 
 147 
The control group consisted of healthy right-handed adults recruited through various 148 
social media platforms. As per usual practice in conducting M1 TMS studies, only right-149 
handed control participants were selected as stimulation over non-dominant M1 has been 150 
associated with accentuated within-subject variability [39, 40]. They self-reported to be 151 
free of all previously mentioned exclusion criteria.    152 
Study participants were also screened for TMS tolerability and safety [41].  153 
 154 
Assessment measures  155 
Total assessment procedures (including consent) were conducted over a single, 90-minute 156 
session. First, participants were invited to complete self-administered questionnaires to 157 
gather demographic information and clinical outcome measures (pain intensity and 158 
functional disability indices). More specifically, demographic data such as age, sex, and 159 
level of education were documented and used to ensure homogeneity between groups.  160 
 161 
Clinical outcome: Pain intensity and functional disability indices 162 
 To assess the perceived level of pain at the time of testing, the numerical rating scale 163 
(NRS), a routinely used standardized generic unidimensional clinical pain questionnaire, 164 
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was administered [42, 43]. To complete the NRS, participants had to circle a number that 165 
best fit their current level of pain on the 11-point pain intensity scale, with numbers 166 
ranging from 0 (“no pain”) to 10 (“worst possible pain”). In order to test the hypothesized 167 
impact of acute pain intensity on M1 cortical excitability, IULF patients were divided 168 
into two distinct groups according to NRS score: 1) IULF patients who self-reported 169 
moderate to severe pain intensity (NRS 4 out of 10); 2) IULF patients with mild pain 170 
intensity (NRS <4). The cut-off pain intensity scores are based on previous pain studies 171 
[10, 44, 45]. 172 
The disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire was used as a tool 173 
to assess an individual’s ability to perform common specific everyday activities relying 174 
on upper extremity limbs [46, 47]. This questionnaire consists of 30 items, including 6 175 
that are symptom-related and 24 that are function-related, where patients were asked to 176 
rate the level of disability on each activity as experienced since their accident. Continuum 177 
of scores on this questionnaire varies between 0 (no disability) and 100 (extreme 178 
difficulty).  179 
 180 
Comprehensive assessment of M1 cortical excitability using TMS.  181 
To assess M1 cortical excitability, a TMS figure-of-eight stimulation coil (80mm wing 182 
diameter), attached to a Bistim2 Magstim transcranial magnetic stimulators (Magstim 183 
Company, Whitland, Dyfed, UK), was used. The TMS-coil was positioned flat on the 184 
scalp over M1 at a 45 angle from the mid-sagittal line, with its handle pointing 185 
backwards. In the IULF group, the TMS coil was positioned over M1 contralaterally to 186 
the injury, whereas in the control group, the TMS-coil was systematically positioned over 187 
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the dominant left hemisphere. Motor evoked potentials (MEP) recordings from the 188 
abductor pollicis brevis (APB) was performed using three electrodes positioned over the 189 
belly of the target muscle (active electrode (+)), between the distal and proximal 190 
interphalangeal joints of the index (reference (-)), and on the forearm (ground). Optimal 191 
stimulation site was determined based on the coil position which evoked highest peak-to-192 
peak MEP amplitudes from the target muscle. We used a 3D tracking system (Northern 193 
Digital Instruments, Waterloo, Canada) to ensure accurate and consistent TMS coil 194 
positioning on the targeted site.  195 
 196 
Various well-established TMS protocols were conducted to investigate M1 excitatory and 197 
inhibitory mechanisms using single and paired-pulse paradigms. Single pulse magnetic 198 
stimulations were first used to establish the resting motor threshold (rMT), i.e. the 199 
minimal stimulation intensity needed to elicit a MEP of at least 0.05mV in five out of ten 200 
trials [48]. An interstimulus interval, varying from 8 to 10 seconds, was applied to control 201 
for possible residual effects of TMS stimulation on M1 activity [49]. The sequence of 202 
stimulation intensity was randomly generated by a computer. Short intra-cortical-203 
inhibition (SICI) and facilitation (ICF) were measured via a classic paired-pulse 204 
paradigm [50, 51]. The latter protocol involves the application of two successive TMS 205 
pulses, the first pulse set at 80% of the rMT intensity (subthreshold; conditioning 206 
stimulus) and the second pulse set at 120% of the rMT (suprathreshold; test stimulus) 207 
separated by an interstimulus interval (ISI) of a predetermined duration [50]. To test for 208 
SICI, a measure attributed to GABAA interneurons and receptors activity [52], one 209 
sequence of 10 paired-pulse stimulations was completed with an ISI set at 3ms. To test 210 
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for ICF, one sequence of 10 stimulations was performed with ISI set at 12ms. Measure of 211 
ICF is thought to be mediated by excitatory glutamatergic interneurons and N-methyl-D-212 
aspartate (NMDA) receptors [52-56]. Results of SICI and ICF are expressed as 213 
percentage ratios of MEP amplitudes. These ratios represent the mean MEP amplitude of 214 
paired TMS over the mean MEP amplitude of the test stimuli baseline measurement (10 215 
single magnetic pulses set at 120% rMT). Therefore, high SICI values reflect a lack of 216 
intracortical inhibition, whereas a low value ICF corresponds to a lack of intracortical 217 
facilitation. Finally, we measured long-interval cortical inhibition (LICI) through paired-218 
pulse TMS of identical subthreshold suprathreshold intensity (i.e. 120% rMT) with an ISI 219 
of 100ms. The first pulse corresponded to the conditioning stimulus whereas the second 220 
pulse was the test stimulus. LICI is primarily known to be mediated by GABAB receptors 221 
[57, 58]. To calculate LICI, we used the percentage ratio between the mean peak-to-peak 222 
MEP amplitude of the test stimulus response (TSR) and the mean peak-to-peak MEP 223 
amplitude of the conditioning stimulus response (CSR) expressed as: mean 224 
(TSR)/mean(CSR). 225 
Statistics 226 
Statistical analyses were performed using IBM SPSS Statistics software version 25 227 
(Armonk, NY, United States). The Shapiro-Wilks test was used to determine the 228 
normality of the data. Parametric and nonparametric tests were performed, where 229 
appropriate, with a -level fixed at 0.05. Descriptive analyses were used to characterize 230 
and compare the three groups (1- IULF patients with NRS4; 2- IULF patients with 231 
NRS<4; 3- healthy controls) in our study sample. Results from descriptive analyses are 232 
expressed as means, standard deviation (SD), and percentages. We used a Student’s t-test 233 
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or a Mann-Whitney U test to investigate group differences on TMS measures. An 234 
analysis of variance (ANOVA) or the Kruskal-Wallis test were also used where 235 
appropriate. Pearson and Spearman’s correlation analysis were also computed to assess 236 
the relationship between functional disability outcomes and the other outcome measures 237 
of interest (pain intensity and TMS measures). We corrected for multiple comparisons 238 
using False Discovery Rate (FDR) where appropriate.  Post-hoc analyses were conducted 239 
to control for the effect of within-group variability of stimulated hemispheres across 240 
IULF patients on TMS measures as it varied according to the injury location (left or 241 
right). Therefore, we elected to create subgroups as follow: IULF patients stimulated over 242 
the left hemisphere (IULF with left-M1) and IULF patients stimulated on the right 243 
hemisphere (IULF with right-M1). Lastly, a post-hoc linear regression analysis was 244 
computed to assess which independent variables between pain intensity (NRS score from 245 
0-10) and the number of days between the accident and testing (independent variable) 246 
best predict significant changes in M1-cortical excitability (dependent variable) in IULF 247 
patients.  248 
 249 
Results  250 
Demographic information 251 
A total of 84 subjects took part in the current study, of which 56 had suffered an IULF 252 
(23 females; mean age: 39.41 years old) and 28 were healthy controls (17 females; mean 253 
age: 34.93). Two subgroups of IULF patients were formed according to pain intensity: 254 
Twenty-five IULF individuals met the criteria for moderate to severe pain (NRS 4), 255 
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whereas 31 IULF subjects were classified as having mild pain (NRS <4). Age (H=3.89; 256 
p=0.14) and sex (F(81)=3.76; p=0.15) did not differ between groups, whereas the level of 257 
education (F(81)=3.95; p=0.02) and the time elapsed between the accident and testing  258 
(U=225.50; p=0.01) were statistically different across groups. More specifically, IULF 259 
patients with NRS4 were tested on average 4.48 (SD=3.50) days post-accident 260 
compared to 7.55 (SD=4.45) days for IULF patients with NRS<4. Spearman’s 261 
correlational analyses revealed a strong association between pain intensity and the extent 262 
of functional disability as measured through the DASH questionnaire (rs=0.76; p<0.001). 263 
Refer to tables 1-2 for additional descriptive information regarding study sample and 264 
fracture distribution among IULF patients.  265 
 266 
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 268 
Table 2. Fracture distribution among IULF patients 269 
Type of fracture N (subjects [%]) 
- Radial head 11(19.64) 
- Collarbone 8 (14.29) 
- Humerus 9 (16.07) 
- Distal radius 21 (37.50) 
- Scaphoid 4 (7.14) 
- Scapula 1 (1.79) 
- Ulna 2 (3.57) 
 270 
 Group differences on M1-cortical excitability measures in relation 271 
to pain threshold 272 
Resting Motor Threshold (rMT) 273 
Mann-Whitney U test revealed that IULF patients with NRS4 did not statistically differ 274 
from IULF patients with NRS<4 (U=324.50; p=0.54) and healthy controls (U=323.50; 275 
p=0.82) on rMT. Similarly, IULF patients with NRS<4 showed equivalent rMT measures 276 
as healthy controls (U=365.00; p=0.39). See Fig 1A.  277 
Fig 1. Groups differences on TMS measures 278 
 279 
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MEPs test stimulus intensity 280 
MEPs of the test stimulus used to measure SICI and ICF were equivalent between 281 
groups. Indeed, IULF patients with NRS4 did not statistically differ from IULF patients 282 
with NRS<4 (U=336.00; p=0.40) and healthy controls (U=304.00; p=0.41). Moreover, 283 
IULF patients with NRS<4 and healthy controls were comparable (U=431.00; p=0.96). 284 
See Fig 1B. 285 
Short intra-cortical inhibition (SICI) 286 
Results showed that IULF patients with NRS 4 statistically differed from healthy 287 
controls (U=202.00; p<0.01), with NRS 4 IULF patients exhibiting reduced short-288 
intracortical inhibition of M1. A tendency toward reduced short-intracortical inhibition 289 
was found in IULF patients with NRS 4 compared to IULF patients with NRS <4, but 290 
the difference failed to reach significance (U=282.50; p=0.08),. Lastly, IULF patients 291 
with NRS<4 and healthy controls showed similar SICI (U=383.00; p=0.44). See Fig 1C. 292 
We then conducted a post-hoc linear regression to assess the contribution of both pain 293 
intensity and delay between the accident and testing on SICI disinhibition. Data shows 294 
that pain intensity at the time of testing significantly predicted SICI disinhibition and 295 
explained 29% of the variance (-coefficient = 0.29; p=0.05), whereas the delay between 296 
the accident and testing poorly predicted SICI disinhibition (-coefficient= 0.07; 0.63).  297 
 298 
 Intra-cortical facilitation (ICF)  299 
IULF patients with NRS4 exhibited a significantly reduced ICF (t(54)=2.44; p=0.02) 300 
relative to IULF patients with NRS<4. IULF patients with NRS4 (t(51)=-1.63; p=0.11) 301 
and IULF with NRS<4 (t(57)=0.37; p=0.71) did not statistically differ from healthy 302 
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controls. See Fig 1D. Results from a post-hoc linear regression showed that pain intensity 303 
significantly predicted altered ICF (-coefficient=-0.30; p=0.04), accounting for 30% of 304 
the variance, whereas delay between the accident and testing (-coefficient=-0.02; 305 
p=0.87) poorly predicted altered ICF. 306 
 307 
Long-interval cortical inhibition (LICI) 308 
IULF patients with NRS4 had similar LICI values compared to IULF patients with 309 
NRS<4 (U=339.00; p=0.42) and healthy controls (U=324.00; p=0.64). IULF patients 310 
with NRS<4 and healthy controls were also equivalent on LICI (U=405.00; p=0.66). See 311 
Fig 1E.  312 
 313 
Post-hoc analyses controlling for the side of the stimulated 314 
hemisphere in IULF patients 315 
To investigate if the stimulated hemisphere had an impact on cortical excitability 316 
measures, IULF patients were stratified into two distinct groups: IULF patients 317 
stimulated on the left M1 and IULF patients stimulated on the right M1. Demographic 318 
data such as age (U=296.00; p=0.12), sex (X2(1)=0.002; p=0.96), education level 319 
(t(54)=1.17; p=0.25), and the timing of testing in relation to the accident (U=339.50; 320 
p=0.39) were similar across groups (see table 3). Lastly, there was no between-group 321 
difference in regard to pain intensity (U=297.50; p=0.12).  322 
 323 
Table 3. Descriptive characteristics of IULF patients according to the stimulated 324 
hemisphere  325 
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U= 297.50 0.12 
 327 
 Group differences on M1-cortical excitability measures in relation to M1 328 
stimulation side 329 
None of the TMS measures differed across IULF patients according to the stimulated 330 
hemisphere [rMT (U=359.00; p=0.93); SICI (U= 377.00; p=0.81); ICF (t(54)=-0.44; 331 
p=0.6); LICI (U= 361.50; p=0.62)]. See Fig 2A-D.  332 
 333 
Relationship between cortical excitability measures and functional disability 334 
outcomes 335 
The DASH questionnaire was used to investigate the relationship between functional 336 
disability outcomes and cortical excitability parameters. Only IULF subjects were 337 
 17 
included in this analysis, whereas healthy controls were excluded. Results show that the 338 
DASH score was strongly associated with SICI (Rs=0.37; p=0.006), whereas no 339 
correlation was found with ICF (r= -0.11; p=0.46), LICI (Rs=-0.06; p=0.67), and rMT 340 
(Rs= 0.18; p=0.22).  341 
 342 
Fig 2A-D. Between IULF-group differences on TMS measures stratified according 343 
to the stimulated hemisphere.  344 
 345 
 346 
Discussion  347 
 348 
This study provides new insights into the involvement of the primary motor cortex in the 349 
early phase of recovery (<14 days post-trauma) following an IULF through various TMS 350 
protocols assessing M1-cortical excitability. More precisely, results suggest a significant 351 
decrease in intracortical inhibition and facilitation in IULF patients over the cortical 352 
representation of the fractured bone. These neurophysiological alterations were only 353 
observed in IULF patients with pain of moderate to severe intensity (NRS 4), whereas 354 
IULF patients with mild pain did not differ from healthy controls. Furthermore, this study 355 
highlights that the time elapsed between the accident and testing within the first 14 days 356 
of the accident, as well as the stimulated hemisphere, do not influence any of the primary 357 
motor cortex excitability measures. On the contrary, pain intensity emerges as the main 358 
factor explaining acute abnormalities of M1 excitability in IULF patients relative to a 359 
healthy cohort of similar age, sex distribution, and education level. To the best of our 360 
knowledge, this is the first study to investigate M1-cortical excitability in acute pain 361 
following an isolated upper limb fracture.  362 
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This study suggests a state of disinhibition through reduced SICI, a TMS measure 363 
that is robustly associated to GABAA receptors activity [52], but only in patients with 364 
moderate to severe pain intensity (NRS 4). Moreover, the extent of SICI disruption was 365 
strongly associated with functional disability scores (DASH). Current findings highlight 366 
possible resemblance across pain states, as SICI disturbances are also found in various 367 
chronic pain conditions [7, 59-61]. A reduction of GABAergic inhibition has been shown 368 
to play a prominent role in chronic pain development and in pain maintenance [62]. It is 369 
therefore no surprise that GABA receptor agonists have proven effective as an analgesic 370 
agent, but important side effects limit its long-term use [63, 64]. Identification of a state 371 
of disinhibition at such an early stage of recovery in patients with a fracture is of 372 
particular clinical relevance in this population since high initial pain is considered a risk 373 
factor for chronic pain development [65]. These results may further our understanding as 374 
to why high levels of pain in the acute phase is considered a risk factor for chronic pain. 375 
Indeed, patients with moderate to severe pain (NRS 4) are affected by disrupted 376 
GABAergic inhibition within the first few days post-trauma, which may hypothetically 377 
contribute to CNS’ vulnerability to pain chronification.  378 
Of note, current findings diverge from results found in experimental acute pain 379 
studies. Experimentally induced pain in healthy controls shows an increase in M1 380 
intracortical inhibition whereas the current study found a decrease in inhibition in IULF 381 
patients presenting with moderate to severe acute pain (NRS 4). Increased SICI in acute 382 
experimental pain has been suggested as an adaptation strategy to prevent CNS 383 
reorganization [32]. Given the reverse pattern of M1 disinhibition in IULF patients, one 384 
should investigate whether moderate to severe pain symptoms in the latter clinical 385 
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population may facilitate lasting CNS reorganization through sustained activation of 386 
plasticity mechanisms. One reason for the discrepancies in SICI findings between 387 
experimental and acute clinical pain could be that fracture pain involves multiple 388 
physiological mechanisms that cannot be replicated in a human experimental setting. For 389 
example, the physiological cascade following tissue injury and bone fracture alone, 390 
including an acute inflammatory response, can modulate brain excitability [66] and 391 
impair GABAergic and glutamatergic activities [67]. Future studies combining both 392 
experimental paradigms in a healthy cohort and clinical pain in OT patients are warranted 393 
if we are to investigate the mechanisms involved and to restrict results discrepancy due to 394 
possible methodological variabilities.  395 
Current results also reveal alterations of intracortical facilitation in IULF patients 396 
with moderate to severe pain (NRS 4), a measure traditionally considered to be 397 
mediated by glutamatergic facilitatory transmission [52-56]. The finding that both ICF 398 
and SICI are reduced may appear counterintuitive from a physiological standpoint. 399 
However, physiological underpinnings of TMS-induced ICF effects have been the subject 400 
of ongoing debate, as some evidence suggest that the latter reflects an overlap between 401 
inhibitory and excitatory mechanisms [54]. Along those lines, pharmacological studies 402 
have shown that both NMDA receptors antagonists (such as dextromethorphan and 403 
memantine) as well as GABAA agonists can modulate ICF. In parallel, some TMS and 404 
chronic pain studies have shown reduced ICF, but this was mainly found in patients with 405 
fibromyalgia [11, 61]. Additional factors relevant to the orthopedic population could also 406 
account for current study findings. For example, other types of pain (muscle pain, bone 407 
pain, etc.) and inflammatory response can influence the balance between inhibitory and 408 
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facilitatory mechanisms [66, 67]. Moreover, limb disuse may also affect brain plasticity 409 
due to reduced sensorimotor input and output [68-70]. 410 
Current findings support work from Pelletier and colleagues [29] suggesting that 411 
pain intensity, rather than pain state, appears to be linked to the extent of motor cortex 412 
excitability alterations. As such, patients who reported moderate to severe pain (NRS 4) 413 
showed accentuated SICI and ICF alterations as compared to patients with mild pain 414 
levels who showed a similar M1 excitability profile to healthy controls. This is 415 
particularly interesting as results from the current study showed that patients with higher 416 
pain levels also reported greater functional disability. Therefore, study findings are not 417 
only consistent with the notion that high initial pain is a good predictor for chronic pain, 418 
but it also argues that altered cortical excitability of M1 could contribute to underlying 419 
mechanisms of pain chronification following a fracture [71, 72].  420 
Although a similar M1-cortical excitability profile may emerge between acute and 421 
chronic injury phases, the involvement of the CNS may be different. One should bear in 422 
mind that altered SICI and ICF in acute pain do not necessarily indicate permanent CNS 423 
reorganization. Although speculative, acute changes in M1-cortical excitability could also 424 
reflect the intensity of the nociceptive afferent originating from the periphery. It should 425 
be noted that the group of patients reporting moderate to severe (NRS 4) pain levels 426 
who also exhibited altered M1-cortical excitability were tested at a significantly shorter 427 
delay following the accident relative to patients who reported mild levels of pain. One 428 
cannot exclude the possibility that alterations of M1-cortical excitability within the first 429 
few days of the injury could have subsided as pain intensity is expected to reduce with 430 
additional time to recover. However, results from linear regressions, used to delimitate 431 
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the weight of the timing of testing in relation to the accident and pain intensity on altered 432 
M1-cortical excitability, showed that pain intensity best predicted altered intracortical 433 
inhibition and facilitation, whereas timing of testing had no impact within that short 14-434 
day time frame. Longitudinal follow-ups are nonetheless needed to investigate 435 
longitudinal changes of TMS-induced M1 excitability measurements in relation with pain 436 
stages, particularly during the transition from acute to chronic pain. 437 
LICI, another measure reflecting GABAB receptors inhibition, was found to be 438 
unrelated to reported pain intensity following a peripheral injury. In a recent review, 439 
authors only found scarce evidence of the involvement of LICI alterations in various 440 
chronic pain conditions [7], either suggesting that GABAB receptors remain intact or that 441 
the latter measure may be less sensitive to pain states. It would still appear relevant to 442 
include other TMS paradigms known to measure GABAA and GABAB receptors, namely 443 
short-afferent inhibition (SAI), long-afferent inhibition (LAI), and the cortical silent 444 
period (CSP) in the context of future studies [54, 73]. This would allow us to deepen our 445 
understanding of the involvement of acute pain on the GABAergic inhibitory system in 446 
IULF patients.  447 
Given the known durable effects of multisession rTMS protocols on M1-cortical 448 
excitability and on pain reduction, rTMS appears as a highly relevant intervention avenue 449 
for the IULF population. Acute rTMS application should be considered as an intervention 450 
option as it may provide analgesic effects to suffering patients, in addition to possibly 451 
tackling cortical excitability changes associated with pain chronification.  452 
One limitation to the current study is the use of a single TMS session to 453 
investigate M1-cortical excitability implications in the acute phase of an IULF in relation 454 
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to pain intensity. Longitudinal studies are needed among this population to further 455 
explore the effects of early M1-cortical excitability dysregulations on recovery. This 456 
would provide valuable insights as to whether acute altered M1-cortical excitability is a 457 
predictor of pain chronification. Secondly, this study uses limited, but well established, 458 
TMS parameters. Still, it should be considered that TMS parameters vary greatly across 459 
studies (e.g. ISI, test and conditioned stimuli intensity), surely contributing to result 460 
variability found in the literature. This poses a challenge for researchers to establish the 461 
most sensitive and specific TMS parameters. In the context of the present study, it should 462 
be considered that previous studies have highlighted possible contamination by short-463 
afferent cortical facilitation (SICF) in SICI according to the TMS parameters used [74, 464 
75]. Although the present study uses parameters from previously published studies, SICF 465 
contamination cannot be excluded. It would be important to account for these findings in 466 
future studies. Moreover, tThe use of additional TMS paradigms (SAI, LAI, CSP) as well 467 
as an objective measure of pain, such as conditioned pain modulation [76, 77], would be 468 
highly relevant in the context of future studies to draw a thorough physiological profile of 469 
ascending and descending tracks in IULF patients with moderate to severe pain (NRS 470 
4). Thirdly, since the initial medical consultations varied across IULF individuals, 471 
timing of testing post-accident was not equivalent within the IULF group. Although post-472 
hoc analyses showed that this factor did not influence TMS outcomes, future studies 473 
should, to the extent possible, assess patients at a fixed day since the physiological 474 
cascade following the injury is rapidly evolving. Fourthly, pain medication usage and 475 
dosage at the time of testing were not restrained in IULF patients, possibly leading to 476 
interindividual variability among the sample. Effects of analgesics medication on cortical 477 
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excitability measures cannot be excluded although very scarce evidence exists. One study 478 
showed that acetaminophen can increase MEP, which facilitates the inhibition of voltage-479 
gated calcium and sodium currents [78]. In this case, and in relation with current study 480 
results showing decreased intracortical inhibition, acetaminophen usage among study 481 
sample could have masked cortical excitability deficiencies. As for opioid analgesics, 482 
only one study mentioned that fentanyl does not alter MEP amplitudes [56], a drug that is 483 
rarely used to treat acute pain. Fifthly, future studies should also account for additional 484 
factors, such as the inflammatory cascade (pro-inflammatory cytokines levels) and 485 
genetic predisposition, as they are known to impact pain intensity and M1-cortical 486 
excitability measures [79-82]. Accounting for such factors would be beneficial to develop 487 
tailored interventions for the IULF population. Sixthly, the stimulated hemisphere (right 488 
or left M1) varied in IULF patients according to the injured side. This factor was 489 
controlled for in IULF patients and no differences were found. On the other hand, all 490 
healthy controls were right-handed and were stimulated on the left-M1, which 491 
corresponds to the dominant hemisphere as per optimal TMS guidelines. Since no 492 
differences were found among the clinical sample, we elected to follow the TMS 493 
guidelines in the healthy sample. Finally, evidence show that reduced use of limb (limb 494 
immobilization) can indeed lead to brain changes (cortical thickness, cortical excitability, 495 
etc.) in the motor cortex due to reduced sensory input/sensorimotor deprivation [68-70, 496 
83]. We can by no mean exclude this factor entirely, but a few points should be 497 
considered. First, IULF patients were tested very early post-injury, leaving less time for 498 
measurable brain changes. Second, statistical analyses show that the number of days 499 
between testing and the accident (possible indicator of reduced limb use) is not associated 500 
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with alterations in cortical excitability measures. Lastly, IULF patients who showed most 501 
cortical excitability deficiencies were actually tested within shorter delays of accident 502 
(NRS >4 group), leaving less time, compared to the other IULF group (NRS<4), for 503 
cortical reorganization due to limb immobilization.   504 
Conclusions 505 
In conclusion, this is the first study to investigate M1 cortical excitability involvement in 506 
an orthopedic trauma population suffering from acute pain. Current results show early 507 
signs of altered GABAergic inhibitory and glutamatergic facilitatory activities in patients 508 
with pain of moderate to severe intensity (NRS 4). These findings may bear major 509 
clinical significance as this population is vulnerable to chronic pain development. Early 510 
detection of at-risk patients could guide proactive intervention aiming to reduce the 511 
likelihood of an unsuccessful recovery in this population, leading to a pathological 512 
condition. This study also highlights that acute application of rTMS may reveal 513 
promising in alleviating pain symptoms among this population and may have 514 
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Reviewer #1  
 
Comment #1: In regard to contamination of SICI by SICF, I was not suggesting to use 
AMT. The issue could have been accounted for by using a lower %RMT conditioning 
stimulus. I understand why the authors would want to include the intensity commonly 
tested within the existing literature, but inclusion of an additional, lower intensity, 
conditioning stimulus would have been very feasible. At the very least, the possibility of 
SICF contamination should be addressed to some degree in the discussion. 
Response to Comment #1: We have addressed this comment in the limitation section. 
 
Comment #2: The authors did not address why they elected to retain outcomes of all 
post-hoc comparisons in the figures, despite the fact that they’re reported in the text (see 
comment 9). 
Response to Comment #2: Our apologies. We have made the necessary changes and 
removed all results from the post-hoc statistics.   
 
Comment #3: Typos on line 224 (RMT criteria still refer to 0.5mV MEP, which should 
be 0.05mv) and 243 (LICI stimuli referred to as subthreshold, should be suprathreshold). 
Response to comment #3: Thank you for picking that up. We have made the necessary 
changes.  
 
Response to Reviewers
